N/A N=419

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Glaucoma, Open-Angle · Ocular Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT01589510 ↗

Enrolled (actual)

419

Serious AEs

0.0%

Results posted

Jun 2014

Primary outcome: Primary: Intraocular Pressure (IOP) at Baseline — 21.23; 21.38 Millimeters of Mercury (mmHg)

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: bimatoprost 0.01% ophthalmic solution (Drug)
Age: Pediatric, Adult, Older Adult · 16+ yrs
Sex: All
Sponsor: Allergan
Primary completion: Feb 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Intraocular Pressure (IOP) at Baseline	21.23; 21.38	—
PRIMARY IOP at Week 14	15.92; 16.05	—
SECONDARY Physician Evaluation of IOP Lowering in the Study Eye(s)	83; 233; 73; 6; 13; 28	—
SECONDARY Patient Assessment of Tolerability on a 4-Point Scale	201; 167; 16; 9	—
SECONDARY Physician Assessment of Tolerability on a 4-Point Scale	209; 171; 8; 4	—
SECONDARY Percentage of Patients Who Discontinue Lumigan® 0.01% Prior to 14 Weeks of Treatment	7.9	—
SECONDARY Percentage of Patients Who Continue Lumigan® 0.01% Treatment	86.2	—
SECONDARY Physician Assessment of Patient Compliance Compared to Previous Therapy	94; 88; 1; 1	—

Summary

A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.

Eligibility Criteria

Inclusion Criteria

Diagnosis of POAG or OHT
Prescribed Lumigan® 0.01%

Exclusion Criteria

None

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01589510). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.